Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Valentina Martin | Cristina Chiriaco | Chiara Modica | Anna Acquadro | Marco Cortese | Francesco Galimi | Timothy Perera | Loretta Gammaitoni | Massimo Aglietta | Paolo M Comoglio | Elisa Vigna | Dario Sangiolo
British journal of cancer | 2019

Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-γ modulation of PD-L1/PD-L2 in MET-amplified tumours.

Pubmed ID: 30723303

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Jackson ImmunoResearch (tool)

RRID:SCR_010488

A commercial antibody vendor, specializing in secondary antibodies.

View all literature mentions

MKN45 (tool)

RRID:CVCL_0434

Cell line MKN45 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions